CorMedix posted $127.4 million in Q1 2026 net revenue — more than three times the $39.1 million it generated in the same period a year ago — but the cleaner story sits underneath that headline number. Strip out the $9.0 million non-recurring sales allowance adjustment and the Melinta anti-infective portfolio acquired last August, and the core DefenCath business still delivered roughly $88 million in organic quarterly revenue. That is a business running well ahead of what most observers expected given the looming expiration of TDAPA, the CMS transitional drug add-on payment adjustment that has functionally subsidized DefenCath’s adoption in outpatient dialysis. The company is not waiting for that cliff to arrive; it is building the revenue base and pipeline to outrun it.
The strategic logic here is straightforward even if the execution risk is real. CorMedix raised full-year 2026 revenue guidance to $325–$345 million and adjusted EBITDA to $115–$135 million. With $178.1 million in cash and a 55% adjusted EBITDA margin in Q1, the company has meaningful financial latitude. The Melinta acquisition — which added $29.9 million this quarter — was not a distraction. It was deliberate portfolio diversification to reduce single-asset dependence precisely because TDAPA exposure was always finite. That acquisition now funds a substantial portion of the commercial infrastructure, keeping DefenCath’s margin profile intact even as selling and marketing spend jumped 180% year-over-year.
The second growth lever is rezafungin. Positive Phase III topline data from the ReSPECT trial in allogeneic stem cell transplant patients, released in late April, gives CorMedix a credible sNDA filing in the second half of this year and a probable 2027 commercial launch for fungal prophylaxis. The antifungal prophylaxis market in this immunocompromised population is underpenetrated and high-value. If the FDA filing proceeds without material complications, rezafungin becomes the third revenue pillar — alongside DefenCath dialysis and the Melinta portfolio — before TDAPA headwinds fully materialize.
The TPN indication for taurolidine-heparin remains on a slower trajectory, with trial completion now targeted for 2028 and an active protocol amendment submitted to FDA to remove exclusion criteria and lift enrollment. That timeline is secondary right now. The number that matters most in the next twelve months is whether rezafungin’s sNDA clears FDA review without a Complete Response Letter — that single regulatory outcome determines whether CorMedix’s post-TDAPA revenue bridge holds.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
